Brodalumab versus ustekinumab in psoriasis

Dermatol Ther. 2016 Sep;29(5):298. doi: 10.1111/dth.12323. Epub 2015 Dec 2.

Authors

Massimo Fioranelli¹, Maria Grazia Roccia², Torello Lotti³

Affiliations

¹ Department of Nuclear Physics, Sub-Nuclear and Radiation, Guglielmo Marconi University, Rome, Italy.
² University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
³ Department of Nuclear Physics, Sub-Nuclear and Radiation, Guglielmo Marconi University, Rome, Italy. professor@torellolotti.it.

PMID: 26627075
DOI: 10.1111/dth.12323

No abstract available

Keywords: brodalumab; monoclonal antibody; psoriasis; ustekinumab.

MeSH terms

Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Clinical Trials, Phase III as Topic
Dermatologic Agents / therapeutic use*
Humans
Psoriasis / diagnosis
Psoriasis / drug therapy*
Psoriasis / immunology
Skin / drug effects*
Skin / immunology
Treatment Outcome
Ustekinumab / therapeutic use*

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatologic Agents
brodalumab
Ustekinumab